Terns Says Phase IIa Data Show Superior NASH Safety Profile In FXR Class

 
• By Joseph Haas

TERN-101 showed a superior safety and tolerability profile for lipid levels and pruritis compared to other FXR agonists in a mid-stage study. Terns is now looking to a NASH combo study with its THR beta agonist.

A professional businessman thinking while standing on a black arrow pointing forward in grey space concept
Terns thinks Phase IIa data for its FXR agonist is a key step in NASH combo therapy plans

More from Clinical Trials

More from R&D